20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Novo Nordisk A/S (NYSE:NVO) continues to bolster its obesity portfolio. In the latest move, the Danish pharma giant has acquired Embark Biotech.
Novo Nordisk will pay upfront of €15 million, and Embark Biotech is eligible to receive potential development, regulatory, and commercial milestones of up to €456 million.
All the biotech's employees will transfer to a new group, Embark Laboratories, to "continue their work and scientific journey."
The new company is focused on cardiometabolic disease and has formed a three-year obesity R&D collaboration with Novo Nordisk.
The remarkable clinical achievements and growing market traction of GLP-1 medications created by Novo Nordisk and Eli Lilly And Co (NYSE:LLY) in the realms of diabetes and obesity have propelled weight loss into a paramount domain within the pharmaceutical industry.
Earlier this month, Novo Nordisk agreed to buy Canada's Inversago Pharma, a metabolic disorders specialist focusing on developing peripherally acting CB1 receptor blocker therapies, for up to $1.075 billion.
Last month, Eli Lilly inked a deal worth $1.9 billion to buy Versanis Bio, bolstering its product profile of obesity-curbing drugs.
The biotech spun out of the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen in 2017, was incubated at Novo Seeds, and announced a research collaboration with Novo Nordisk in 2018.
Price action: NVO shares are down 0.40% at $189.60 on the last check Wednesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!